Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years

Trial Profile

Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Rabies vaccine (Primary)
  • Indications Rabies
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Jun 2015.
    • 13 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top